Literature DB >> 30036573

Safety evaluation through genotoxicity and apoptotic markers following RISUG® induced contraception and its reversal in male rabbits.

A S Ansari1, A Badar2, N K Lohiya3.   

Abstract

The safety evaluation following vas occlusion with RISUG® and its reversal with DMSO and NaHCO3, using genotoxicity tests and apoptotic marker assays, was carried out in rabbits. Animals were divided into groups of sham operated control, vas occlusion with RISUG® for 3 & 12 months, reversal with DMSO and NaHCO3 after 3 & 12 months, respectively. Minimum incidences of micronuclei in erythrocytes and frequency of aberrant chromosomes were observed. Caspase-3 and TUNEL positive cells in testis and cauda epididymis sections were observed within control limits. Comet assay in leukocytes and testicular cells revealed damaged cell range at the control level. DNA damage in cauda epididymal spermatozoa was observed between 2-3 % by in vitro study and annexin V assay indicated a significant enhancement (p < 0.05) of positive cells in 3 months vas occlusion group. In conclusion, RISUG® induced occlusion and its reversal has not been correlated with any toxicity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cauda epididymis; Genotoxicity; Leukocytes; RISUG(®); Spermatozoa; Testis

Mesh:

Substances:

Year:  2018        PMID: 30036573     DOI: 10.1016/j.reprotox.2018.07.083

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  2 in total

1.  Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience.

Authors:  Radhey Shyam Sharma; Ajit Kumar Mathur; Rajeev Singh; Hem Chandra Das; Gulshan Jeet Singh; Devinder Pal Singh Toor; Sujoy Kumar Guha
Journal:  Indian J Med Res       Date:  2019-07       Impact factor: 2.375

2.  RISUG® as a male contraceptive: journey from bench to bedside.

Authors:  Barkha Khilwani; Ayesha Badar; Abdul S Ansari; Nirmal K Lohiya
Journal:  Basic Clin Androl       Date:  2020-02-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.